Compare UAN & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UAN | CDNA |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2008 | 2007 |
| Metric | UAN | CDNA |
|---|---|---|
| Price | $125.90 | $48.61 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 36.1K | ★ 1.1M |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | ★ 7.91% | N/A |
| EPS Growth | ★ 61.98 | N/A |
| EPS | ★ 12.06 | 2.13 |
| Revenue | ★ $606,038,000.00 | $48,324,000.00 |
| Revenue This Year | N/A | $16.01 |
| Revenue Next Year | N/A | $11.31 |
| P/E Ratio | ★ $10.32 | $22.06 |
| Revenue Growth | 15.36 | ★ 18.93 |
| 52 Week Low | $86.43 | $12.37 |
| 52 Week High | $139.50 | $49.76 |
| Indicator | UAN | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 59.86 | 71.19 |
| Support Level | $121.55 | $16.20 |
| Resistance Level | $130.40 | $49.76 |
| Average True Range (ATR) | 3.31 | 1.85 |
| MACD | 0.03 | -0.39 |
| Stochastic Oscillator | 83.06 | 93.01 |
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.